OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
Benzinga
OCTOBER 4, 2024
Following the transactions, OnKure is expected to have a cash runway through multiple clinical readouts and into Q4-2026. "We 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. and Reneo Pharmaceuticals, Inc. The combined company will operate under the name OnKure Therapeutics, Inc., President and Chief Executive Officer of OnKure.
Let's personalize your content